Understanding how GSTP1 affects advanced prostate cancer
Official title: Delineate the Role of GSTP1 in Advanced Prostate Cancer
Funded at University of California Los Angeles · NIH-11090536 · Data updated 2026-11-12
This study is looking at a protein called GSTP1 to see how it affects advanced prostate cancer that doesn't respond to hormone therapy, and it aims to find out if targeting this protein could help improve treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 14, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $452,888 |
| NIH project number | 5R01CA274978-03 |
| Project ID | NIH-11090536 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those whose disease has become resistant to hormone therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone hormone therapy may not benefit from this research.
What this research studies
This research investigates the role of the GSTP1 protein in advanced prostate cancer, particularly in cases that have become resistant to hormone therapy. The study aims to explore how GSTP1 contributes to the aggressive nature of the disease and to evaluate the potential of targeting this protein as a new treatment strategy. Using patient-derived xenograft models, researchers will test the effects of inhibiting GSTP1 alone and in combination with cisplatin, a chemotherapy drug, to determine its therapeutic benefits. The ultimate goal is to uncover mechanisms that drive treatment resistance and to develop more effective therapies for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for men with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.